-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Crosses Below Fifty Day Moving Average of $3.65
ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Crosses Below Fifty Day Moving Average of $3.65
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating)'s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.65 and traded as low as $2.85. ZIVO Bioscience shares last traded at $3.02, with a volume of 6,150 shares.
ZIVO Bioscience Trading Down 0.3 %
The stock has a market capitalization of $28.45 million, a price-to-earnings ratio of -3.05 and a beta of -0.05. The firm has a 50-day moving average of $3.65 and a 200 day moving average of $3.56.
Get ZIVO Bioscience alerts:ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Insider Activity at ZIVO Bioscience
In other ZIVO Bioscience news, Director Christopher D. Maggiore bought 7,200 shares of the stock in a transaction that occurred on Wednesday, September 14th. The shares were purchased at an average cost of $3.53 per share, for a total transaction of $25,416.00. Following the transaction, the director now directly owns 810,305 shares in the company, valued at $2,860,376.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 17.10% of the stock is owned by insiders.Hedge Funds Weigh In On ZIVO Bioscience
An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. raised its position in shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 92,468 shares of the biotechnology company's stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned about 0.98% of ZIVO Bioscience worth $359,000 as of its most recent SEC filing. 5.04% of the stock is owned by institutional investors.
About ZIVO Bioscience
(Get Rating)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Featured Articles
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating)'s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.65 and traded as low as $2.85. ZIVO Bioscience shares last traded at $3.02, with a volume of 6,150 shares.
Zivo Bioscience，Inc.(场外交易代码：Zivo-Get Rating)的股价在周二的交易中跌破了50日移动均线。该股的50日移动均线为3.65美元，最低交易价格为2.85美元。Zivo Bioscience的股票最新报3.02美元，成交量为6,150股。
ZIVO Bioscience Trading Down 0.3 %
Zivo生物科学公司股价下跌0.3%
The stock has a market capitalization of $28.45 million, a price-to-earnings ratio of -3.05 and a beta of -0.05. The firm has a 50-day moving average of $3.65 and a 200 day moving average of $3.56.
该股市值为2,845万美元，市盈率为-3.05，贝塔系数为-0.05。该公司的50日移动均线切入位在3.65美元，200日移动均线切入位在3.56美元。
ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Zivo Bioscience(场外交易市场代码：Zivo-Get Rating)最近一次公布财报是在8月4日星期四。这家生物技术公司公布了本季度每股收益(0.22美元)。
Insider Activity at ZIVO Bioscience
Zivo Bioscience的内部活动
Hedge Funds Weigh In On ZIVO Bioscience
对冲基金参与Zivo Bioscience
An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. raised its position in shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 92,468 shares of the biotechnology company's stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned about 0.98% of ZIVO Bioscience worth $359,000 as of its most recent SEC filing. 5.04% of the stock is owned by institutional investors.
一家机构投资者最近提高了对Zivo Bioscience股票的头寸。先锋集团在最近提交给美国证券交易委员会的13F文件中称，该公司第一季度将其在Zivo Bioscience，Inc.(场外交易代码：Zivo-Get)的股票持仓上调了19.6%。该机构投资者在本季度额外购买了15,147股后，持有这家生物技术公司92,468股股票。据先锋集团最新提交的美国证券交易委员会申报文件显示，该公司持有Zivo Bioscience约0.98%的股份，价值35.9万美元。5.04%的股份由机构投资者持有。
About ZIVO Bioscience
关于Zivo生物科学
(Get Rating)
(获取评级)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Zivo Bioscience，Inc.是一家研发公司，致力于向动物、人类、膳食补充剂和医用食品制造商许可和销售从其专有藻类培养物中提取的天然生物活性成分。它在生物技术和农业技术部门开展业务，拥有知识产权组合，包括专有藻类和细菌菌株、生物活性分子和复合体、生产技术、栽培技术，以及应用于人类和动物健康的专利或正在申请专利的发明。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
- 免费获取StockNews.com关于Zivo生物科学的研究报告(Zivo)
- 防御性股票应对动荡的市场
- SunPower准备推动三位数的收益增长
- UPS会成为下一个发出警告的公司吗？
- 这是Gap Stock黎明前最黑暗的一次吗？
- 与捷普公司一起打造更好的技术产品组合。
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
获得Zivo生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Zivo Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧